Cite
MLA Citation
Alexandra Calmy et al.. “Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.” Lancet, vol. 7, no. 10, 2020, pp. e677–e687. http://access.bl.uk/ark:/81055/vdc_100110822313.0x000005